Akorn, Inc.-Strides Arcolab Limited Announces its First ANDA Approval For Keterolac Tromethamine Injection USP, 15 mg/mL and 30 mg/mL

BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Akorn-Strides, LLC today announced its first ANDA approval for Keterolac Tromethamine Injection USP, 15 mg/mL and 30 mg/mL. Akorn-Strides, LLC is a Joint Venture that was formed in 2005 by Akorn, Inc. (NASDAQ: AKRX) and Strides Arcolab Limited (NSE: STAR)(BSE: 532531). The primary mission for the Joint Venture is developing liquid, lyophilized and dry powder fill generic injectable products targeting several therapeutic markets with a major focus on anti-infectives, analgesics and CNS medicines.